These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28647165)

  • 1. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
    Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Gottlieb SL; Giersing BK; Hickling J; Jones R; Deal C; Kaslow DC;
    Vaccine; 2019 Nov; 37(50):7408-7418. PubMed ID: 29224963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine value profile for herpes simplex virus.
    Johnston C; Scheele S; Bachmann L; Boily MC; Chaiyakunapruk N; Deal C; Delany-Moretlwe S; Lee S; Looker K; Marshall C; Mello MB; Ndowa F; Gottlieb S
    Vaccine; 2024 Jul; 42(19S1):S82-S100. PubMed ID: 39003018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.
    Gorfinkel IS; Aoki F; McNeil S; Dionne M; Shafran SD; Zickler P; Halperin S; Langley J; Bellamy A; Schulte J; Heineman T; Belshe R
    Int J STD AIDS; 2013 May; 24(5):345-9. PubMed ID: 23970700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
    Ghiasi H
    J Virol; 2017 Dec; 91(23):. PubMed ID: 29138327
    [No Abstract]   [Full Text] [Related]  

  • 6. Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.
    Spicknall IH; Looker KJ; Gottlieb SL; Chesson HW; Schiffer JT; Elmes J; Boily MC
    Vaccine; 2019 Nov; 37(50):7396-7407. PubMed ID: 29625767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
    Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L
    Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.
    Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M
    J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
    Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
    Schiffer JT; Gottlieb SL
    Vaccine; 2019 Nov; 37(50):7363-7371. PubMed ID: 28958807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.
    Wang K; Dropulic L; Bozekowski J; Pietz HL; Jegaskanda S; Dowdell K; Vogel JS; Garabedian D; Oestreich M; Nguyen H; Ali MA; Lumbard K; Hunsberger S; Reifert J; Haynes WA; Sawyer JR; Shon JC; Daugherty PS; Cohen JI
    J Infect Dis; 2021 Nov; 224(9):1509-1519. PubMed ID: 33718970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential prophylactic and therapeutic vaccines for HSV infections.
    Ramachandran S; Kinchington PR
    Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?
    Posavad CM; Wald A; Hosken N; Huang ML; Koelle DM; Ashley RL; Corey L
    J Immunol; 2003 Apr; 170(8):4380-8. PubMed ID: 12682275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccines as an approach to the immunocorrection in herpetic infections].
    Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
    Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.
    Görander S; Harandi AM; Lindqvist M; Bergström T; Liljeqvist JÅ
    J Virol; 2012 Jul; 86(14):7544-53. PubMed ID: 22553328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown.
    Chentoufi AA; Kritzer E; Yu DM; Nesburn AB; Benmohamed L
    Clin Dev Immunol; 2012; 2012():187585. PubMed ID: 22548113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of developing a herpes simplex virus 2 vaccine.
    Dropulic LK; Cohen JI
    Expert Rev Vaccines; 2012 Dec; 11(12):1429-40. PubMed ID: 23252387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.